Pharmacologic profile of certoparin

Bibliography

• ANDERSON FA, WHEELER HB, GOLDBERG RJ et al.: A population-based perspective of the hospital inci-dence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch. Intern. Med. (1991) 151:933–938.
   PubMed Web of Science ®Google Scholar
• CREAGER MA, BECKMAN JA: Assessment of arterial and venous thrombosis. In: Thrombosis and Hemorrhage. Loscalzo J, Schafer Al (Eds.), Williams and Wilkins, Balti-more (1998):491–516.
   Google Scholar
• GILLUM RF: Pulmonary embolism and thrombophlebi-tis in the United States. Am. Heart J. (1987) 114:1262–1264.
   PubMed Web of Science ®Google Scholar
• HIRSH J, LEVINE M: The development of low molecular weight heparins for clinical use. In: Thrombosis and Haemostasis. Verstraete M et al. (Eds.), Leuven University Press, Leuven (1987):425–448.
   Google Scholar
• HULL R, DELMORE T, CARTER C et al.: Adjusted subcuta-neous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. New Engl. J. Merl. (1983) 306:954–958.
   Google Scholar
• NIEUWENHUIS HK, ALBADA J, BANGA JD, SIXMA JJ: Iden-tification of risk factor for bleeding during treatment of acute venous thrombosis with heparin or low mo-lecular weight heparin. Blood (1991) 78 (9) :2337–2343.
   PubMed Web of Science ®Google Scholar
• BERGQVIST D, MATZSCH T, BURMARK US et al: Low mo-lecular weight heparin given the evening before sur-gery compared with conventional low-dose heparin in the prevention of thrombosis. Br. J. Surg. (1988) 75 (9) :888–891.
   PubMed Web of Science ®Google Scholar
• EUROPEAN FRAXIPARIN STUDY GROUP: Comparison of low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br. J. Surg. (1988) 75:1058–1063.
   PubMed Web of Science ®Google Scholar
• MONREAL M, LAFOZ E, NAVARRO A et al. A prospective double-blind trial of low molecular weight heparin once daily compared with conventional low dose heparin three times daily to prevent pulmonary embo-lism and venous thrombosis in patients with hip frac-ture. J. Trauma (1989) 29(6):873–875.
   PubMed Web of Science ®Google Scholar
• PLANES A, VOCHELLE N, MAZAS F et al.: Prevention of postoperative venous thrombosis. A randomized trial comparing unfractionated heparin with low molecu-lar weight heparin in patients undergoing total hip re-placement. Thromb. HaemosL (1988) 60 (3) 407–410.
   Google Scholar
• ERIKSSON BI, ZACHRISSON BE, TEGER-NILSSON AC, RISHERG B: Thrombosis prophylaxis with low molecu-lar weight heparin in total hip replacement. Br. J. Surg. (1988) 75 (1 1) :1053–1057.
   Google Scholar
• BORRIS LC, HAUCH 0, JORGENSEN LN, LASSEN MR: Enoxaparin versus dextran 70 in the prevention of post-operative deep vein thrombosis after total hip re-placement. A Danish multicenter study. Proceedings of the Danish Enoxaparin Symposium (3 February 1990).
   Google Scholar
• TURPIE AGG, LEVINE MN, HIRSH J et al.: A randomized controlled trial of low molecular weight heparin (Enoxaparin) to prevent deep vein thrombosis in pa-tients undergoing elective hip surgery. New Engl. J. Med. (1987) 315:925–929.
   Web of Science ®Google Scholar
• AHSAN A, JESKE W, MARDIGUIAN J, FAREED J: Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins. J. Pharm. Sci. (1994) 83(2):197–201.
   PubMed Web of Science ®Google Scholar
• WOLF H: Structural and Functional Characterization of a Low Molecular Weight Heparin and its Lower Molecular Weight Fraction. University of Regensberg (1997).
   Google Scholar
• DAVIE EW, RATNOFF OD: Waterfall sequence for intrin-sic blood clotting. Science (1964) 145:1310–1312.
   PubMed Web of Science ®Google Scholar
• MACFARLANE RG: An enzyme cascade in the blood clot-ting mechanism and its function as a biochemical am-plifier. Nature (1964) 202:498–499.
   PubMed Web of Science ®Google Scholar
• EDGINGTON TS, MACKMAN N, BRAND K, RUF W: The structural biology of the expression and function of tissue factor. Thromb. HaemosL (1991) 66:67–79.
   PubMed Web of Science ®Google Scholar
• MOUREY L, SAMAMA JP, DELARUE M et al.: Antithrombin III: structural and functional aspects. Biochemie (1990) 72:599–608.
   PubMed Web of Science ®Google Scholar
• PRATT CW, CHURCH FC: Antithrombin: structure and function. Semin. Hematol (1991) 28(0:3–9.
   PubMedGoogle Scholar
• PIZZO SV: The physiologic role of antithrombin III as an anticoagulant. Semin. Hematol. (1994) 31(2)4–7.
   Google Scholar
• BJORK I, DANIELSSON A: Antithrombin and related in-hibitors of coagulation proteinases. In: Proteinase In-hibitors. Barrett AJ, Salvesen GS (Eds.), Elsevier, Amsterdam, The Netherlands (1986) :489–513.
   Google Scholar
• TRAVIS J, SALVESEN GS: Human plasma proteinase in-hibitors. Ann. Rev. Biochem. (1983) 52:655–709.
   PubMed Web of Science ®Google Scholar
• ROSENBERG RD, DAMUS PS: The purification and mechanism of action of human antithrombin - hepa-rin cofactor. J. Biol. Chem. (1973) 248:6490–6505.
   PubMed Web of Science ®Google Scholar
• JORNVALL H, FISH WW, BJORK I: The thrombin cleavage site in bovine antithrombin. FEBS Lett. (1979) 106:358-362. DAMUS PS, HICKS M, ROSENBERG RD: Anticoagulant ac-tion of heparin. Nature (1973) 246:355-357. OWEN MC, BORG JY, SORIA C, SORIA J, CAEN J, CARRELL PW: Heparin binding effect in a new antithrombin III variant: Rouen 47 Arg to His. Blood (1987) 69:1275–1279.
   Google Scholar
• ROSENBERG RD: Actions and interactions of anti-thrombin and heparin. New. Engl. J. Med. (1975) 292:146–151.
   PubMed Web of Science ®Google Scholar
• PETERSON CB, BLACKBURN MN: Antithrombin confor-mation and the catalytic role of heparin II. Is the heparin-induced conformational change in anti-thrombin required for rapid inactivation of thrombin? J. Biol. Chem. (1987) 262:7559–7566.
   Google Scholar
• FAREED J, HOPPENSTEADT D, JESKE W, CLARIZIO R, WALENGA JM: Low molecular weight heparins: a devel-opmental perspective. Exp. Opin. Invest. Drugs (1997) 6(6)705–733.
   Google Scholar
• FAREED J, WALENGA JM, HOPPENSTEADT D, RACANELLIA, COYNE E: Chemical and biochemical heterogeneity in low molecular weight heparins: implications for clinical use and standardization. Semin. Thromb. He-most. (1989) 15:440–463.
   PubMed Web of Science ®Google Scholar
• WELZEL D: Clinical and pharmacological aspects ofLMW heparins in the prophylaxis of thromboses. Hae-mostasis (1986):141.
   Google Scholar
• HELLSTERN P, KIEHL R, VON BLOHN G, KOHLER M, MEIERHENRICH U, WENZEL E: Dose response relation-ship of anticoagulant activities after subcutaneous ad-ministration of two low molecular weight heparins in healthy individuals. Thromb. Haemost. (1986) 56:225–228.
   PubMed Web of Science ®Google Scholar
• WARNING A, NIES D, WOLF H, WELZEL D: Effect of lowmolecular weight heparin on coagulation parameters and bleeding time in healthy volunteers. Drug. Res. (1987) 37:847.
   Web of Science ®Google Scholar
• HOPPENSTEADT DA, HAAS S, BREDDIN HK, FAREED J:Modulation of laboratory parameters after therapeutic and prophylactic administration of Sandoparin. Semin. Thromb. Hemost. (1993) 19\(Suppl. 1):31–35.
   Google Scholar
• LOJEWSKI B, BACHER P, IQBAL 0 et al.: Evaluation of he-mostatic and fibrinolytic alterations associated with daily administration of low-molecular-weight heparin for a 12-week period. Semin. Thromb. Hemost. (1995) 21(2):228–239.
   Google Scholar
• GROBECKER H, WELZEL D, DITTRICH W, BACHER P: Pharmakokinetik und Bioverfugbarkeit von nieder-molekularem Heparin-Sandoz mit 1.500 und 2.500 aPTT Einheiten. Study Report (1994).
   Google Scholar
• GRASSMAN ED, LEYA FS, LEWIS BE et al. The low mo- lecular weight heparin certoparin may significantly prevent restenosis following balloon coronary angio-plasty. JOURNAL (1997) 96(8):I–323.
   Google Scholar
• KIRCHMAIER CM, WOLF H, SCHAFER H, EHLERS B, BRED-DIN HK: Efficacy of a low molecular weight heparin ad-ministered intravenously or subcutaneously in comparison with intravenous unfractionated heparin in the treatment of deep venous thrombosis. JOURNAL (1998) 17(3):135–145.
   Google Scholar
• HARBAUER G, GROBECKER H: Pharmacologisches Sachverstandigen-Gutachten uber Niedermolekelares Heparin (NMH) der Sandoz AG Nurnberg. Study Report (1984).
   Google Scholar
• WEICHERT W, BREDDIN HK: Effect of low-molecular-weight heparins on laser-induced thrombus forma-tion in rat mesenteric vessels. Haemostasis (1988) 18\(Suppl. 3):55–63.
   Google Scholar
• FU K, IZQUIERDO R, VANDEVENDER D, WARPEHA RL, WOLF H, FAREED J: Topical application of low molecu-lar weight heparin in a rabbit traumatic anastomosis model. Thromb. Res. (1997) 86(5):355–361.
   PubMed Web of Science ®Google Scholar
• BACHER P, WELZEL D, IQBAL 0 et al.: The thrombolytic potency of LMW-heparin compared to urokinase in a rabbit jugular vein clot lysis model. Thromb. Res. (1992) 66:151–158.
   Google Scholar
• HARENBERG J, MALSCH R, ANGELESCU M et al.: Antico-agulant effects and tissue factor pathway inhibitor af-ter intrapulmonary low-molecular-weight-heparin. Blood Coag. Fibrinol. (1996) 7(4):477–483.
   PubMed Web of Science ®Google Scholar
• HARENBERG J, ZIMMERMAN R: Neutralization of intra-venously administered low molecular weight heparin Sandoz by intravenous administration of protamine chloride. Study Report (1985).
   Google Scholar
• LOJEWSKI B, BACHER P, IQBAL 0 et al: Evaluation of he-matologic alterations associated with daily admini-stration of low molecular weight heparin (Mono-Embolex) for a 12-week period. Semin. Thromb. Hemost. (1993) 19\(Suppl. 1):36–43.
   Google Scholar
• HEINRICH D, GORG T, SCHULZ M: Effects of unfraction-ated heparin on platelet function. Haemostasis (1988) 18\(Suppl. 3):48–54.
   Google Scholar
• WESTWICK J, SCULLY MF, POLL C, KAKKAR VV: Compari-son of the effects of low molecular weight heparin on the activation of platelets in vitro. Thromb. Res. (1986) 42:435–447.
   PubMed Web of Science ®Google Scholar
• HAAS S: Effect of s.c. administration of different doses of cracked and unfractionated heparin on blood co-agulation parameters. Study on cumulative effects. Study Report (1985).
   Google Scholar
• WOLZT M, EDER M, WELTERMANN A, ENTLICHER J, EICHLER HG, KYRLE PA: Comparison of the effects of different low molecular weight heparins on the hemo-static system activation in vivo in man. Thromb. Hemost. (1997) 78:876–879.
   PubMed Web of Science ®Google Scholar
• FAREED J: Low molecular weight heparins beyond pro-phylaxis. Potential use in the management of vascular and cardiovascular disorders. 17th World Congress of the International Union of Angiology. London (3–7 April 1995).
   Google Scholar
• PIAZOLO L, HARENBERG J, MALSCH R, HUTTNER FG,HEENE DL: Comparison of the pharmacodynamic and pharmacokinetic profiles of two low-molecular-mass heparins in rats. Semin. Thromb. HemosL (1997) 23 (2):109–117.
   PubMed Web of Science ®Google Scholar
• HAAS S: Double-blind comparison of the efficacy and safety of low molecular weight heparin 1500 IU (aPTT) and low molecular weight heparin 1500 IU (aPTT) in fixed combination with dihydroergotamine (Embolex NM) in patients undergoing elective hip replacement. Clinical Study Report (1989). Data on file.
   Google Scholar
• LOWE GDO: Epidemiology of post-operative deep vein thrombosis and pulmonary embolism. Semin. Thromb. Hemostas. (1991) 17\(Suppl. 3)247–249.
   Google Scholar
• KAKKAR W: A prospective, randomised double-blind trial to assess the safety and efficacy of low molecular weight heparin compared with low molecular weight heparin and dihydroergotamine in the prevention of post-operative thromboembolic disease following hip arthroplasty. Clinical Study Report (1989). Data on file.
   Google Scholar
• BERGQVIST D: Invited commentary. World J. Surgery (1992) 16:984–985.
   Google Scholar
• OERTLI D, HESS P, DURIG M et al.: Prevention of deep vein thrombosis in patients with hip fractures: low molecular weight heparin versus dextran. World J. Surg. (1992) 16:980–984.
   PubMed Web of Science ®Google Scholar
• HOFFMANN R, KOHLER A, TRENZ 0, BISCHOF T: Pro-phylaxis of venous thromboembolism in patients with hip fractures: unfractionated heparin (Liquemin) versus low molecular weight heparin (Sandoparin). 17th World Congress of the International Union of Angiol-ogy. London (3–7 April 1995).
   Google Scholar
• KOPPENHAGEN K, MATTHES M, HARING R, TROSTER E, WOLF H, WELZEL D: Thromboembolieprophylaxe in der abdominalchirurgie. vergleich der wirksamkeit und vertraglichkeit von niedermolecularem heparin und unfraktioniertem heparin. Munch. Med. Wschr. (1990) 132:677–680.
   Google Scholar
• KOPPENHAGEN K, ADOLF J, MATTHES M et al.: Low mo-lecular weight heparin and prevention of post-operative thrombosis in abdominal surgery. Thromb. HemosL (1992) 67:627–630.
   PubMed Web of Science ®Google Scholar
• ADOLF J, KNEE J, RODER JD, VAN DE FLIERDT E, SEWERT JR: Thromboembolieprophylaxe mit niedermolekula-rem Heparin in der Abdominalchirurgie. Dtsch. Med. Wschr. (1989) 114:48–53.
   PubMedGoogle Scholar
• KAKKAR W: A prospective, randomised double-blindtrial of low molecular weight heparin and unfraction-ated heparin in the prevention of venous thrombosis. A multi-unit study. Clinical Study Report (1989). Data on file.
   Google Scholar
• HEILMANN L, KRUCK M, SCHINDLER AE: Thrombosepro-phylaxe in der Gynakologie: Doppelblind Vergleich zwischen niedermolekularem (LMWH) und unfrak-tioniertem (UFH) Heparin. Geburtsh Frauenheilk (1989) 49:803–807.
   PubMedGoogle Scholar
• HARENBERG J, SCHNEIDER D, HEILMANN L, WOLF H: Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis (1993) 23:314–320.
   PubMedGoogle Scholar
• KOCHLI OR, BENZ J: Der Einsatz von niedermolekula-rem Heparin zur thromboembolieprophylaxe im Wo-chenbett. Sandorama (1990) 4:35–40.
   Google Scholar
• HARENBERG J, KALLENBACH B, MARTIN U et al.: Ran-domized controlled study of heparin and low molecu-lar weight heparin for prevention of deep vein thrombosis in medical patients. Thromb. Res. (1990) 59:639–650.
   PubMed Web of Science ®Google Scholar
• KOCK HJ, SCHMIT-NEUERBURG K, HANKE J, RUDOFSKY G, HIRCHE H: Thromboprophylaxis with low molecu-lar weight heparin in outpatients with plaster cast im-mobilisation of the leg. Lancet (1995) 346:459–461.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, LEVINE MN, HIRSH J et al.: Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated hepa-rin. New Engl. J. Med. (1995) 332:1330–1335.
   PubMed Web of Science ®Google Scholar
• RAIBLE MD, WOLF H, LEYA F et al.: Post-PTCA genera-tion of HEP-PF4 antibodies is associated with previous exposure to unfractionated heparin. Studies with the chronic administration of a LMWH. Blood (1995) 86 (10) :551a. Walter Jeske", Helmut Wolf2 Ahmad Ahsan1 & Jawed Fareed3 tAuthor for correspondence
   Google Scholar